Analysts flagged concerns over achieving oncology revenue targets amid dependency on ENHERTU’s growth to offset Datroway’s ...

After a string of new approvals, Daiichi Sankyo is boosting sales projection for AstraZeneca-partnered star cancer drug Enhertu. Daiichi now expects Enhertu could reach sales of 195.2 billion ...

Enhertu logged sales of $3.75 billion in Daiichi’s 2024 fiscal year, which concluded at the end of March. The company is projecting sales of the treatment to reach 662 billion Japanese yen in ...

Daiichi Sankyo and AstraZeneca's ENHERTU has received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for the treatment of a specific type of metastatic ...

Enhertu is an antibody drug conjugate (ADC) that was discovered by Daiichi Sankyo and is being further developed and commercialized under a partnership with AstraZeneca. The antibody component of ...

Daiichi Sankyo has a leading ADC platform, a cutting-edge modality for cancer treatments that improves upon the safety and efficacy of existing chemotherapy treatments. Enhertu has demonstrated ...

As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first time in messaging efforts. Daiichi ...

MADRID—Daiichi Sankyo and ADC partner AstraZeneca finally have some clarity on the deaths that occurred in a pair of phase 3 studies for their Enhertu follow up Dato-DXd. The gist of the safety ...

Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca's ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications with ...

Following this approval for Enhertu in the U.S., AstraZeneca is due $175 million as a milestone payment to Daiichi Sankyo. Daiichi Sankyo recognizes Enhertu sales in the U.S. AstraZeneca reports ...

Enhertu + pertuzumab showed significant PFS improvement vs. THP in HER2+ metastatic breast cancer in DESTINY-Breast09 trial. Interim OS data favored Enhertu combo; safety profile aligned with ...